TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Duality Biotherapeutics, Inc. ( (HK:9606) ) has provided an update.
Duality Biotherapeutics, Inc. announced its interim results for the first half of 2025, highlighting a 22.9% increase in revenue compared to the same period in 2024, despite a significant loss for the period. The company has made substantial progress in its pipeline development, including the FDA’s Fast Track Designation for its HER3-targeting ADC DB-1310 and the initiation of a Phase 1/2 clinical study for DB-1418/AVZO-1418. These advancements, alongside promising clinical trial data presented at major oncology conferences, underscore Duality’s commitment to innovation in cancer treatment and its potential impact on the biotherapeutics industry.
The most recent analyst rating on (HK:9606) stock is a Hold with a HK$344.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a company incorporated in the Cayman Islands, focusing on biotherapeutics with a strong emphasis on developing advanced drug candidates for cancer treatment. The company is actively involved in clinical trials and pipeline advancements, particularly in the areas of antibody-drug conjugates (ADCs) and bispecific antibodies, aiming to address unmet medical needs in oncology.
Average Trading Volume: 273,716
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$30.71B
For an in-depth examination of 9606 stock, go to TipRanks’ Overview page.